文献速递糖尿病肥胖与代谢综合征

基线GLP-1受体激动剂使用对非奈利酮联合恩格列净疗效与安全性的影响:CONFIDENCE试验预设分析

Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial).
PubMed 文献 · Diabetes Care · 2025-01-01

CONFIDENCE试验的预设分析评估基线使用GLP-1受体激动剂(GLP-1 RA)是否影响非奈利酮联合恩格列净的疗效与安全性。800例2型糖尿病合并慢性肾脏病患者中182例(23%)基线使用GLP-1 RA,第180天联合治疗组尿白蛋白/肌酐比值(UACR)降幅在用药者与未用药者中分别为-51%和-56%,高钾血症发生率分别为9.0%和9.5%,eGFR变化一致。联合治疗有效且耐受良好,不受基线GLP-1 RA使用影响。

要点

  • 联合治疗UACR降幅在基线用与不用GLP-1 RA者中分别为-51%和-56%。
  • 高钾血症发生率联合治疗组在用药者与未用药者中分别为9.0%和9.5%。
  • eGFR变化在两组间一致,急性肾损伤不常见。

核心结论

  • 同时起始非奈利酮与SGLT2抑制剂相比单药治疗有效且耐受良好,不受基线GLP-1 RA使用影响。

研究设计与样本

  • CONFIDENCE试验的预设分析,800例2型糖尿病合并慢性肾脏病(UACR≥100至<5000 mg/g,eGFR 30-90 mL/min/1.73 m2,糖化血红蛋白<11%)患者随机(1:1:1)接受非奈利酮、恩格列净或联合治疗。

主要发现

  • 182例(23%)基线使用GLP-1 RA。
  • 第180天,基线使用GLP-1 RA者UACR变化:联合治疗-51%(95%CI -59至-40%),非奈利酮-34%(-48至-18%),恩格列净-36%(-48至-21%)。
  • 基线未使用GLP-1 RA者UACR变化:联合治疗-56%(-62至-50%),非奈利酮-37%(-45至-28%),恩格列净-33%(-41至-23%)。
  • 联合治疗高钾血症发生率在基线使用与未使用GLP-1 RA者中分别为9.0%和9.5%。
  • eGFR变化在基线使用与未使用GLP-1 RA者中一致,急性肾损伤不常见,联合治疗收缩压下降更明显。

临床怎么用

  • 对于2型糖尿病合并慢性肾脏病患者,无论是否使用GLP-1 RA,均可考虑同时起始非奈利酮与SGLT2抑制剂以降低白蛋白尿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The CONFIDENCE trial demonstrated additive benefits of simultaneous initiation of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, and a sodium-glucose cotransporter 2 (SGLT2) inhibitor compared with monotherapy in reducing the urinary albumin-to-creatinine ratio (UACR). This prespecified analysis evaluated whether safety and efficacy of combination therapy varies by baseline glucagon-like peptide 1 receptor agonist (GLP-1 RA) use. RESEARCH DESIGN AND METHODS: Adults with chronic kidney disease (UACR ≥100 to <5,000 mg/g; estimated glomerular filtration rate [eGFR] 30-90 mL/min/1.73 m2) and type 2 diabetes (glycated hemoglobin <11% [97 mmol/mol]) were randomized (1:1:1) to once-daily finerenone, empagliflozin, or finerenone plus empagliflozin. RESULTS: Among 800 participants, 182 (23%) used a GLP-1 RA at baseline. At day 180, UACR change from baseline in participants using a GLP-1 RA was -51% (95% CI -59 to -40%) with combination therapy, -34% (-48 to -18%) with finerenone, and -36% (-48 to -21%) with empagliflozin. Corresponding results in those not using a GLP-1 RA at baseline were -56% (-62 to -50%), -37% (-45 to -28%), and -33% (-41 to -23%), respectively. Hyperkalemia incidence rates with combination therapy were 9.0% and 9.5% among individuals with and without baseline GLP-1 RA use. eGFR changes were consistent among individuals with and without baseline GLP-1 RA use. Acute kidney injury was uncommon. Decreases in systolic blood pressure were observed and were more pronounced with combination therapy. CONCLUSIONS: In CONFIDENCE, simultaneous initiation with finerenone and an SGLT2 inhibitor was effective and well tolerated compared with monotherapy, irrespective of background use of a GLP-1 RA.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Agarwal R, Green JB, Heerspink HJL, et al. Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial). Diabetes Care. 2025. PMID: 40968755. doi:10.2337/dc25-1673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。